Skip to content

Assessment of Tolerance and Effectiveness of Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-517477-24-00
Acronym
20-NIO-0001
Enrollment
40
Registered
2024-11-18
Start date
2022-02-17
Completion date
Unknown
Last updated
2025-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia, myelodysplastic syndromes

Brief summary

The probability of progression-free survival in 24 month FU.

Detailed description

Frequency of adverse events in 24 month FU., 24-month overall survival probability., Disease recurrence probability., Mortality unrelated with disease recurrence., Likelihood of acute and chronic graft-versus-host disease., Time of neutrophil and platelet implantation.

Interventions

DRUG1 mg/ml

Sponsors

Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
The probability of progression-free survival in 24 month FU.

Secondary

MeasureTime frame
Frequency of adverse events in 24 month FU., 24-month overall survival probability., Disease recurrence probability., Mortality unrelated with disease recurrence., Likelihood of acute and chronic graft-versus-host disease., Time of neutrophil and platelet implantation.

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026